Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma ( icient method for producing Id/KLH immu...)

Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

icient method for producing Id/KLH immunotherapies, but also the added advantage of making them potentially more active as well."

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan(R) induction therapy in patients with follicular B-cell NHL in January 2006. Analysis of the primary endpoint, time to disease progression, is event driven and currently projected to occur during the fourth quarter of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:12/15/2009)... NASHVILLE, Tenn. and GLEN ROCK, N.J., Dec. 15 ... 70 percent of surveyed pharmacy directors expect to ... the treatment of chronic pain. Tanezumab, which is ... chronic pain and is administered intravenously under medical ... benefit rather than a pharmacy benefit according to ...

(Date:12/15/2009)... Accumetrics, Inc., developer and marketer of ... diagnostic system for measuring an individual,s response to ... doubling in the number of international and U.S. ... support, and significant capital financing that will take ... the company continued its commitment to creating a ...

(Date:12/14/2009)... Dec. 14 BioTrends Research Group, Inc. ... a syndicated publication offering comprehensive insight into the ... based on a comparison of self-reported treatment approaches ... level data for over 1,000 RA patients who ... To be eligible for the audit, patients had ...

Breaking Medicine Technology:Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2 Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3 Accumetrics Closes 2009 with Positive Outlook 2 Accumetrics Closes 2009 with Positive Outlook 3 New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2 New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3 PAREXEL Introduces The Expert Office 28TM 29 Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 60751 1 PAREXEL Introduces The Expert Office 28TM 29 Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 60751 2 PAREXEL Introduces The Expert Office 28TM 29 Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 60751 3 PAREXEL Introduces The Expert Office 28TM 29 Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 60751 4 PAREXEL Introduces The Expert Office 28TM 29 Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 60751 5 LenSar 3A New Laser Cure for Cataracts 6005 1 LenSar 3A New Laser Cure for Cataracts 6005 2 Superior Global Solutions Inc Acquires HTI Technologies Inc 60747 1 Superior Global Solutions Inc Acquires HTI Technologies Inc 60747 2

[0] Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain [0] Accumetrics Closes 2009 with Positive Outlook [0] New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis

... - Genmab A/S (CSE: GEN),announced today that the ... in patients with rheumatoid,arthritis (RA) have been accepted ... of Rheumatology (EULAR). The oral,presentation, which will include ... study with ofatumumab, along with data,from the previous ...

... 26, 2007,/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , ... announced that,the two-year data from its European ... ("Vascular Wrap(TM)"),will be presented today at a ... the safety and efficacy of the Vascular,Wrap(TM) ...

Other Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2 Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3 Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4 Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5 Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6 Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7

New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study,in Rheumatoid Arthritis to be Presented at EULAR Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium

(Date:12/15/2009)... Dec. 15 Today, Coastal Healthcare ... Clara County for the first time since ... Coastal Healthcare Administrators will be assuming responsibilities ... Physicians Foundation for Medical Care. ,, ... Coastal maintains close working relationships with all ...

(Date:12/15/2009)... often treated with hormones, but when the tumours start ... reveals a thesis from the Sahlgrenska Academy, at the ... for new treatments for hormone-resistant prostate cancer. , Late ... cancer has spread, most patients are given hormone therapy. ... and the tumour shrinks. , "The problem is that ...

(Date:12/15/2009)... by The University of Western Ontario reveals that couples ... report higher average measures of happiness and life satisfaction ... roles, category, where each partner,s unpaid work is within ... a growing category that now represents more than 25 ... be in a shared roles model when women have ...

(Date:12/15/2009)... 2009) Although seen as a potential heart ... inhibiting activity of a transfer protein may not be ... Mayer USDA Human Nutrition Research Center on Aging (USDA ... of Medicine found an association between low plasma cholesterol ... heart disease in the Framingham Heart Study population. , ...

(Date:12/15/2009)... a bizarre about-face, the secretive Central Intelligence Agency has requested ... earlier obtained them from the CIA itself under the Freedom ... ... (Vocus) December 15, 2009 -- In a bizarre about-face, the ... journalist, even though the writer had earlier obtained them from ...

Breaking Medicine News(10 mins):Health News:Coastal Healthcare Administrators Expands Provider Network to Santa Clara County 2 Health News:More blood vessels in hormone-resistant prostate tumors 2 Health News:Low cholesterol transfer protein activity associated with heart disease risk 2 Health News:CIA Requests its Own Documents from Author 2 Health News:CIA Requests its Own Documents from Author 3

[0] Coastal Healthcare Administrators Expands Provider Network to Santa Clara County [0] More blood vessels in hormone-resistant prostate tumors [0] Couples who do the dishes together stay happier [0] Low cholesterol transfer protein activity associated with heart disease risk [0] CIA Requests its Own Documents from Author

... galectin-3 finds them sooner, could cut unnecessary surgeries ... nodules for the presence of a lectin molecule called ... and reduce the number of unnecessary surgeries, according to ... determining whether a nodule is malignant is to examine ...

... Detroit bring up the rear, survey says , , MONDAY, May ... hearts in tip-top shape face the fewest challenges in Minneapolis, ... the list of the 10 most heart-healthy U.S. metropolitan areas ... But the list, released Monday by the American Heart Association, ...

... However, ... Doctor Visits Are Still Needed -, WILMINGTON, Del., ... become increasingly aware of a potentially,serious condition called Gastroesophageal ... 6.1 million Hispanics in the United,States suffer from GERD(1). ...

... - Company Reports Record Revenue and Gross Margin Performance - ... $18.1 million - ... 2008 -, PLYMOUTH MEETING, Penn., May 19 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation ... results from the first quarter of 2008. The,Company intends to file its ...

... MedCath Corporation,(Nasdaq: MDTH ), its physician ... today that the parties have completed the sale ... terms of the,transaction, Good Samaritan purchased substantially all ... Net proceeds to MedCath, after income tax expense ...

... Appointed as Board Chairman, CLEVELAND, May 19 ... services company focused on global,eClinical solutions for the clinical ... team in several key positions as,part of a broad ... Mr. Laurence Birch, currently a member of the ...

Protein Helps ID Thyroid Cancer Nodules Minneapolis Tops List of Heart-Healthy Cities for Women New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD BMP Sunstone Reports First Quarter 2008 Financial Results MedCath Announces Completion of Sale of Dayton Heart Hospital to Good Samaritan Hospital-Dayton DATATRAK Announces Restructured Senior Management Team

BD Beaver DeBakey blade, 5 mm cutting width, sterile....

... They are made of optical quality acrylic and are ... two sets available providing a full range of prisms. ... patient can wear the prism with the trial frame ... adapt to the use of the prism. Patient feedback ...

Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....

Corneal rust ring remover battery powered, extra burr 1.0 mm....

Medicine Products:

BD Beaver DeBakey blade Seven Trial Rings Model 1990 Dermatome Algerbrush Lens Manipulator

( icient method for producing Id/KLH immu...)Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma,Health